| ONC201 and imipridones: Anti-cancer compounds with clinical efficacy VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff, J Ray, A Jhaveri, ... Neoplasia 22 (12), 725-744, 2020 | 120 | 2020 |
| Immunotherapy for colorectal cancer: mechanisms and predictive biomarkers L Carlsen, KE Huntington, WS El-Deiry Cancers 14 (4), 1028, 2022 | 35 | 2022 |
| Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer S Zhang, L Carlsen, L Hernandez Borrero, AA Seyhan, X Tian, ... Biomolecules 12 (4), 548, 2022 | 34 | 2022 |
| MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection L Zhou, K Huntington, S Zhang, L Carlsen, EY So, C Parker, I Sahin, ... Oncotarget 11 (46), 4201, 2020 | 24 | 2020 |
| Differential p53-mediated cellular responses to DNA-damaging therapeutic agents L Carlsen, WS El-Deiry International Journal of Molecular Sciences 22 (21), 11828, 2021 | 23 | 2021 |
| Integrating molecular biomarker inputs into development and use of clinical cancer therapeutics AD Louie, K Huntington, L Carlsen, L Zhou, WS El-Deiry Frontiers in Pharmacology 12, 747194, 2021 | 23 | 2021 |
| Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 delta and omicron pseudovirus infection of airway epithelial cells in vitro, which could attenuate disease severity KE Huntington, L Carlsen, EY So, M Piesche, O Liang, WS El-Deiry Pharmaceuticals 15 (5), 618, 2022 | 19 | 2022 |
| The role of p53 in anti-tumor immunity and response to immunotherapy L Carlsen, S Zhang, X Tian, A De La Cruz, A George, TE Arnoff, ... Frontiers in Molecular Biosciences 10, 1148389, 2023 | 14 | 2023 |
| Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation L Carlsen, WS El-Deiry Frontiers in Oncology 12, 998388, 2022 | 13 | 2022 |
| Therapeutic targeting of autophagy in pancreatic ductal adenocarcinoma AG Raufi, NR Liguori, L Carlsen, C Parker, L Hernandez Borrero, S Zhang, ... Frontiers in pharmacology 12, 751568, 2021 | 12 | 2021 |
| Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal … L Carlsen, C Schorl, K Huntington, L Hernandez-Borrero, A Jhaveri, ... Oncotarget 12 (20), 2006, 2021 | 11 | 2021 |
| Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer L Groysman, L Carlsen, KE Huntington, WH Shen, L Zhou, WS El-Deiry American Journal of Cancer Research 11 (12), 6086, 2021 | 10 | 2021 |
| Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients S Leaf, L Carlsen, WS El-Deiry Oncotarget 12 (20), 1992, 2021 | 9 | 2021 |
| Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells L Zhou, K Huntington, S Zhang, L Carlsen, EY So, C Parker, I Sahin, ... Biorxiv, 2020 | 9 | 2020 |
| An optical surface applicator for intraoperative photodynamic therapy S Chamberlain, D Bellnier, S Yendamuri, J Lindenmann, T Demmy, ... Lasers in surgery and medicine 52 (6), 523-529, 2020 | 9 | 2020 |
| Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells Z Gonzalez, L Carlsen, WS El-Deiry American Journal of Cancer Research 13 (1), 216, 2023 | 4 | 2023 |
| Integrin KE Huntington, L Carlsen, EY So, M Piesche, O Liang, WS El-Deiry TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus …, 2022 | 3 | 2022 |
| Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling B Verschleiser, W MacDonald, L Carlsen, KE Huntington, L Zhou, ... American Journal of Cancer Research 13 (7), 2878, 2023 | 2 | 2023 |
| ITGB6 as a predictive biomarker for overall prognosis and PD-(L) 1 immune checkpoint blockade response in various cancer types WJ MacDonald, PR Srinivasan, M Pinho-Schwermann, V Tajiknia, ... Cancer Research 84 (6_Supplement), 5140-5140, 2024 | 1 | 2024 |
| Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1 WJ MacDonald, B Verschleiser, L Carlsen, KE Huntington, L Zhou, ... American Journal of Cancer Research 13 (7), 2938, 2023 | 1 | 2023 |
